Trials / Completed
CompletedNCT00334152
Casopitant And ZOFRAN To Prevent Post Operative Nausea And Vomiting In Women
A Phase III Multicenter, Randomized, Double-blind, Parallel Group Study to Evaluate the Safety and Efficacy of the 30 mg Intravenous Formulation of the Neurokinin-1 Receptor Antagonist GW679769 for Prevention of Postoperative Nausea and Vomiting in Female Subjects at High Risk for Emesis
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 515 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is being conducted to see if adding GW679769 (casopitant) to ZOFRAN will significantly decrease the number of patients who experience nausea and vomiting after surgery.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | casopitant |
Timeline
- Start date
- 2006-03-01
- Primary completion
- 2006-07-01
- Completion
- 2006-07-01
- First posted
- 2006-06-06
- Last updated
- 2017-03-23
Locations
70 sites across 11 countries: United States, Belgium, Canada, Czechia, Germany, Hong Kong, Pakistan, Philippines, Russia, Spain, Thailand
Source: ClinicalTrials.gov record NCT00334152. Inclusion in this directory is not an endorsement.